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Abstract
Background: Although previous studies have identified high levels of drug-related harm in Thailand, little is known 
about illicit drug overdose experiences among Thai drug users. We sought to investigate non-fatal overdose 
experiences and responses to overdose among a community-recruited sample of injection drug users (IDU) in 
Bangkok, Thailand.
Methods: Data for these analyses came from IDU participating in the Mit Sampan Community Research Project. The 
primary outcome of interest was a self-reported history of non-fatal overdose. We calculated the prevalence of past 
overdose and estimated its relationship with individual, drug-using, social, and structural factors using multivariate 
logistic regression. We also assessed the prevalence of ever witnessing an overdose and patterns of response to 
overdose.
Results: These analyses included 252 individuals; their median age was 36.5 years (IQR: 29.0 - 44.0) and 66 (26.2%) were 
female. A history of non-fatal overdose was reported by 75 (29.8%) participants. In a multivariate model, reporting a 
history of overdose was independently associated with a history of incarceration (Adjusted Odds Ratio [AOR] = 3.83, 
95% Confidence Interval [CI]: 1.52 - 9.65, p = 0.004) and reporting use of drugs in combination (AOR = 2.48, 95% CI: 1.16 
- 5.33, p = 0.019). A majority (67.9%) reported a history of witnessing an overdose; most reported responding to the 
most recent overdose using first aid (79.5%).
Conclusions: Experiencing and witnessing an overdose were common in this sample of Thai IDU. These findings 
support the need for increased provision of evidence-based responses to overdose including peer-based overdose 
interventions.
Background
Accidental illicit drug-related overdose is a leading cause
of preventable morbidity and mortality. In many settings,
fatal overdose is the primary contributor to highly ele-
vated mortality rates among injection drug users (IDU)
[1,2]. According to several studies of community-
recruited IDU, non-fatal overdose is common and associ-
ated with factors including having a prior history of over-
dose, recent incarceration and higher-intensity forms of
drug use, such as poly-drug use [3-6]. Several interven-
tions to lower the incidence or reduce the damaging
sequelae of overdose events have been implemented,
including treatment for drug use [7], drug substitution
therapy [8], supervised injection facilities [9] and peer-
driven responses, such as naloxone distribution [10].
Despite reports of injection drug use from all major
regions of the world [11,12], the phenomenon of acciden-
tal drug overdose has not been well described outside of
Western settings. In northern Vietnam, over 80% of out-
of-treatment male opiate injectors reported a history of
overdose in a cross-sectional survey [13]. Overdose in the
previous 12 months was common among 731 IDU in
Sichuan province, China, and associated with daily her-
oin use and an injection career of at least seven years in
duration [14].
In Thailand, some aspects of drug-related harm,
including high levels of incarceration [15], persecution by
police [16] and infection with HIV [17,18] hepatitis C [19]
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and other pathogens [20] have been identified among the
estimated 20,000 - 160,000 IDU in the country [11,12].
However, we are unaware of any study that analyses the
phenomenon of overdose among Thai drug users. Thus,
we sought to estimate the prevalence and correlates of
non-fatal overdose, as well as investigate patterns of
response to overdose in a community-recruited sample of
active IDU in Bangkok, Thailand.
Methods
Data for these analyses was obtained from the Mit Sam-
pan Community Research Project (MSCRP), a collabora-
tive research effort involving the Mit Sampan Harm
Reduction Center (Bangkok, Thailand), the Thai AIDS
Treatment Action Group (Bangkok, Thailand), Chula-
longkorn University (Bangkok, Thailand) and the British
Columbia Centre for Excellence in HIV/AIDS (Vancou-
ver, Canada). In 2008, the research partners designed and
undertook a cross-sectional epidemiological study of IDU
recruited through peer-based outreach and word-of-
mouth. Invited participants were asked to attend the Mit
Sampan Harm Reduction Center to be included in the
study. All participants provided informed consent and
completed an interviewer-administered questionnaire.
The survey instrument elicited demographic data, infor-
mation about past and current drug use, HIV risk behav-
iour, overdose experiences, interactions with the criminal
justice system including police forces and incarceration,
and experience with health care. Upon completion of the
questionnaire participants were provided a stipend of 250
Thai baht. The study was approved by the research ethics
boards at the University of British Columbia and Chula-
longkorn University.
For these analyses, the primary endpoint of interest was
reporting a history of non-fatal overdose by answering
"Yes" to the question: "Have you ever overdosed by acci-
dent (i.e., a period of loss of consciousness or breathing?)"
In follow-up questions, individuals reporting a history of
non-fatal overdose were also asked the type of drug or
drugs they were using at the time of their last overdose, if
they were helped, and by who, during their last overdose.
As a first step, we investigated the characteristics of
individuals with a history of overdose. Explanatory vari-
ables included: Age; gender (male vs. female); education
level (<prathom suksa [elementary-level] vs. ≥ prathom
suksa); reporting any income from illegal sources (yes vs.
no); participation in the sex trade (yes vs. no); history of
heroin injection (yes vs. no); history of Midazolam (a
benzodiazepine) injection (yes vs. no); history of yaba
(methamphetamine and caffeine) injection (yes vs. no);
history of ice (methamphetamine) injection (yes vs. no);
history of using drugs in combination (yes vs. no); history
of methadone injection (yes vs. no); ever using an unster-
ile syringe (yes vs. no); ever lending syringes (yes vs. no);
ever incarcerated (yes vs. no); ever on methadone mainte-
nance therapy (MMT) (yes vs. no); and ever in forced
drug treatment (yes vs. no). Pearson's X2-test and Fisher's
exact test were used to determine bivariate relationships.
Next, we used an a priori-defined statistical protocol
based on examination of the Akaike Information Crite-
rion (AIC) and p-values to construct an explanatory mul-
tivariate logistic regression model. First, we constructed a
full model including all variables analysed in bivariate
analyses. After noting the AIC of the model, we removed
the variable with the largest p-value and built a reduced
model. We continued this iterative process until no vari-
ables remained for inclusion. We selected the multivari-
ate model with the lowest AIC score.
In a secondary analysis, all participants were asked if
they had ever witnessed an overdose. Those with a his-
tory of witnessing overdose were asked about their
response to the most recently witnessed overdose. Finally,
all participants were asked if they believed they had
enough information to prevent and manage overdose and
what steps they believe should be taken to effectively
manage overdose.
Results
Two-hundred fifty-two individuals were recruited and
included in these analyses, of whom 66 (26.1%) were
women. The median age at time of interview was 36.5
years (IQR: 29.0 - 44.0 years.) In total, 75 participants
(29.8%) reported a history of non-fatal overdose. When
asked about the type and routes of administration of all
drugs consumed prior to their last overdose, almost all
(70, 93.3%) reported injection heroin, followed by injec-
tion Midazolam (24, 32.0%), non-injection heroin (11,
14.7%) and non-injection midazolam (4, 5.3%). No other
response (including injection and non-injection yaba,
non-injection ecstasy, injection and non-injection metha-
done, injection and non-injection benzodiazepine and
injection and non-injection alcohol) exceeded three
(4.0%) reports.
Of the 75 participants with a history of overdose, 59
(78.7%) reported being helped by another individual dur-
ing their last overdose. Most reported being assisted by a
friend (46, 78.0%), relative (11, 18.6%) or sex partner (3,
5.1%). Of all individuals reporting an overdose, only 28
(33.5%) reported being seen by a healthcare professional.
Results of the univariate analyses of factors associated
with reporting a history of non-fatal overdose are pre-
sented in Table 1. As shown, the outcome was associated
at the p < 0.05 level with: reporting a history of incarcera-
tion (Odds Ratio [OR] = 4.40, 95% Confidence Interval
[CI]: 1.80 - 10.79); a history of using drugs in combination
(OR = 3.05, 95% CI: 1.53 - 6.07); and a history of injecting
Midazolam (OR = 2.20, 95% CI: 1.67 - 4.12). A history of
injecting heroin was significantly associated with report-Milloy et al. Harm Reduction Journal 2010, 7:9
http://www.harmreductionjournal.com/content/7/1/9
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Table 1: Univariate analyses of factors associated with reporting a history of non-fatal overdose among IDU in MSHRC 
cohort (n = 252 individuals).
Characteristic History of overdose n (%) OR1 95% CI2 p-val
No: 177 (70.2) Yes: 75 (29.8)
AGE
Median (IQR) 37.0 (29.5 - 44.5) 35.0 (28.0 - 42.0) 0.99 0.97 - 1.03 0.843
GENDER
Male 130 (73.4) 56 (74.7)
Female 47 (26.6) 19 (25.3) 0.93 0.51 - 1.74 0.877
EDUCATION
≥ Secondary 110 (62.1) 50 (66.7) 1.00
< Secondary 37 (37.9) 25 (33.4) 0.82 0.47 - 1.45 0.568
SEX TRADE
No 167 (94.4) 71 (94.7) 1.00
Yes 10 (5.6) 4 (5.3) 0.94 0.29 - 3.10 0.841
EVER INJECT HEROIN
No 18 (10.1) 0 (0.0)
Yes 159 (89.9) 75 (100.0 0.002
EVER INJECT YABA
No 66 (37.3) 25 (33.3) 1.00
Yes 111 (62.7) 50 (66.7) 1.19 0.67 - 2.10 0.570
EVER INJECT MIDAZOLAM
No 66 (37.3) 16 (21.3) 1.00
Yes 111 (62.7) 59 (78.7) 2.20 1.67 - 4.12 0.018
EVER INJECT BENZODIAZEPINES
No 174 (98.3) 73 (97.3) 1.00Milloy et al. Harm Reduction Journal 2010, 7:9
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ing ever experiencing a non-fatal overdose (p = 0.002);
however, as all individuals with a history of overdose also
reported a history of heroin injection, an Odds Ratio
could not be calculated and that explanatory factor was
removed from further consideration. The final multivari-
ate model, presented in Table 2, included two factors
independently associated with the outcome: Ever using
drugs in combination (Adjusted Odds Ratio [AOR] =
2.48, 95% CI: 1.16 - 5.33) and reporting a history of incar-
ceration (AOR = 3.83, 95% CI: 1.52 - 9.65).
Experience witnessing an overdose was reported by 171
(67.9%) participants. When asked their response to the
last overdose witnessed, most (136, 79.5%) reported per-
forming first aid; 78 (45.6%) took the overdose sufferer to
a hospital; 4 (2.3%) took them to the Mit Sampan Harm
Reduction Centre; 1 (0.6%) contacted the police. Twelve
individuals (7.0%) reported they did nothing in response.
Approximately half of the participants reported they
believed they had enough information to prevent (139,
55.2%) and manage (128, 50.8%) an overdose. When
asked how to manage an overdose, responses were: per-
form first aid (115, 45.6%); inject salt water (109, 43.2%);
perform CPR (90, 35.7%); slap (105, 41.7%); administer
naloxone (16, 6.3%); or take to a hospital (74, 29.4%).
Discussion
In these analyses, we found a history of non-fatal over-
dose was common among Thai IDU, with more than one-
quarter of the sample (29.8%) reporting a previous over-
dose event. The predominant drug implicated in over-
Yes 3 (1.7) 2 (2.7) 1.59 0.26 - 9.71 0.636
EVER INJECT METHADONE
No 150 (84.7) 63 (84.0) 1.00
Yes 27 (15.3) 12 (16.0) 1.06 0.50 - 2.22 0.851
EVER USE DRUGS IN COMBINATION
No 65 (36.7) 12 (16.0) 1.00
Yes 112 (63.3) 63 (84.0) 3.05 1.53 - 6.07 < 0.001
EVER INCARCERATED
No 49 (27.7) 6 (8.0) 1.00
Yes 128 (72.3) 69 (92.0) 4.40 1.80 - 10.79 < 0.001
EVER ON MMT
No 102 (57.7) 39 (52.0) 1.00
Yes 75 (42.3) 36 (48.0) 1.26 0.73 - 2.16 0.488
EVER IN FORCED DRUG TREATMENT
No 127 (71.8) 45 (60.0) 1.00
Yes 50 (28.2) 30 (40.0) 1.69 0.96 - 2.82 0.076
1. Odds Ratio; 2. 95% Confidence Interval
Table 1: Univariate analyses of factors associated with reporting a history of non-fatal overdose among IDU in MSHRC 
cohort (n = 252 individuals). (Continued)Milloy et al. Harm Reduction Journal 2010, 7:9
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dose events was heroin, with the majority of individuals
reporting injecting heroin before their last overdose and
every individual with a history of overdose also reporting
a history of heroin use. In a multivariate model, a history
of overdose was linked to poly-drug use and incarcera-
tion. Most of the participants also reported experience
witnessing an overdose (67.9%) and the most common
responses included performing first aid and taking the
victim to a hospital. When asked how to manage an over-
dose, the most common responses included performing
first aid or artificial respiration and injecting salt water.
The level of non-fatal overdose observed in this sample
is on the lower end of the range of estimates calculated in
similar studies of community-based IDU in Baltimore,
Maryland (24.7%) [21]; London, England (37.8%) [22] and
San Francisco, California (47.9%) [23]. We are unable to
determine if this comparatively lower level is the result of
a lower incidence of overdose among Thai IDU or a
g r e a t e r  r i s k  o f  d e a t h  a t  e a c h  o v e r d o s e  e v e n t .  S e v e r a l
points of evidence support a contribution from the latter
effect, including the high prevalence of witnessing over-
doses; the pervasive level of misperceptions concerning
how to manage an overdose; the high prevalence of over-
dose as the reported cause of death among Thai IDU in
two HIV vaccine preparatory studies [24,25]; and the
ongoing violent crackdown by Thai police against drug
users, a phenomenon linked to a greater risk of overdose
mortality in other settings [26-28].
Our findings identify the need for enhanced education
for Thai IDU to prevent and manage overdoses. Specifi-
cally, approximately half of respondents indicated they
did not have the information required to prevent and
manage overdoses. This lack of knowledge was reflected
in the substantial proportion of participants reporting
inappropriate responses, including injecting the sufferer
with salt water. Given that witnessing an overdose was
common in this setting and fatal overdoses typically take
hours to develop [29,30], the need to improve peer
responses is clear. Inappropriate or suboptimal responses
by IDU to overdose are not uncommon and have been
reported from a number of settings [26,29,31]. However,
overdose management education has been shown to be
effective at training IDU to respond appropriately to
overdose [26,32].
These findings also support the distribution of nalox-
one to drug users. Naloxone, an opiate antagonist, is the
standard treatment used by healthcare professionals in
resuscitation efforts following opioid overdose. Programs
to train IDU in overdose response alongside distribution
of naloxone would likely benefit Thai IDU, given that opi-
ates were the most common class of drugs reported by
this sample prior to their last overdose. Additionally,
given pervasive anti-drug user stigma [33,34] and the
ongoing violent campaign by police [35], many IDU may
be unwilling to seek professional health care in the event
of an overdose. Evaluations of analagous interventions in
Chicago [36], New York City [10] and San Francisco [37]
have observed positive impacts, including hundreds of
successful peer opioid overdose resuscitations. Currently,
n a l o x o n e  i s  o n l y  a v a i l a b l e  t o  I D U  i n  T h a i l a n d  a t  t h e
MSHRC.
In the multivariate model, a history of incarceration
was independently associated with ever overdosing. This
is in line with previous analyses that have identified a
high risk of overdose, including fatal overdose, associated
with incarceration, especially in the first weeks following
release from detention [38,39]. In the Thai context, previ-
ous studies have described the links between exposure to
correctional environments and an elevated risk of HIV
infection among IDU [40,41]. Our findings add evidence
supporting the need for an expansion of harm reduction
opportunities in Thai correctional settings, such as sub-
stitution therapies, shown effective at reducing HIV risk
Table 2: Multivariate logistic regression analysis of factors associated with reporting a history of non-fatal overdose in 
MSHRC cohort (n = 252 individuals).
Characteristic AOR1 95% CI2 p-value
Ever injected Midazolam (Yes 
vs. no)
1.38 0.68 - 2.81 0.379
Ever used in combination (Yes 
vs. no)
2.48 1.16 - 5.33 0.020
Ever incarcerated (Yes vs. no) 3.83 1.52 - 9.65 0.004
Ever in forced treatment (Yes 
vs. no)
1.25 0.69 - 2.28 0.457
1. Adjusted Odds Ratio; 2. 95% Confidence IntervalMilloy et al. Harm Reduction Journal 2010, 7:9
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behaviours [42] and improving outcomes post-release
[43].
While the implementation of peer-based interventions
might lower the incidence and severity of overdose events
among Thai IDU, our findings also have implications for
other social- and structural-level policies. In particular,
our findings are another example of how the reliance on
enforcement-based strategies to respond to illicit drug
use can produce further drug-related harms [44,45]. Just
as some observers have identified deaths resulting from
the Thai government's crackdown on drug users [35], our
findings describe how criminal justice interventions can
increase the risks associated with overdose events. We
echo other authors who have credited the country's suc-
cessful efforts to reduce the incidence of sexually-trans-
mitted HIV infections to the government's adoption of
evidence-based policies [41,46] and urge a similar prag-
matic initiative to replace dominant enforcement- and
suppression-based policies with harm reduction pro-
grammes.
Our study has limitations. First, cross-sectional analy-
ses are unable to determine the temporal relationship
between outcome and exposure. Second, although our
measures are based on self-reports from IDU, we do not
believe participants would have been more or less likely
to report a history of overdose based on the covariates we
examined. Finally, our sample of IDU was not recruited at
random and thus may not necessarily generalize to other
samples of IDU in Thailand or other settings.
Conclusions
We observed that non-fatal overdose events were com-
mon in this sample of Thai IDU. In a multivariate analy-
sis, reporting a history of non-fatal overdose was
independently associated with ever being incarcerated
and ever using drugs in combination. A majority of par-
ticipants reported witnessing overdoses as well as need-
ing more information to respond appropriately. Our
findings support the need to expand appropriate harm
reduction strategies for drug users in Thailand, such as
peer-based overdose management including naloxone
distribution, and further highlight the need to balance the
current emphasis on enforcement-based responses to
illicit drug use with health-focused interventions.
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